factually
Index/Organizations/NVX-CoV2373

NVX-CoV2373

Vaccine against COVID-19

Fact-Checks

2 results
Nov 19, 2025
Most Viewed

Do mRNA and non-mRNA 2025 COVID-19 boosters differ in side-effect profiles across ages?

Available reporting shows both 2024–25/2025 updated mRNA boosters (Pfizer, Moderna) and a protein‑subunit booster (Novavax/Nuvaxovid) were offered and monitored for safety; several studies and news an...

Jan 15, 2026

How did two‑dose NVX‑CoV2373 trial efficacy compare to single‑dose immunobridged approvals for variant‑updated vaccines?

Two well-controlled phase 3 trials of the recombinant protein vaccine NVX‑CoV2373 showed high clinical efficacy for a two‑dose primary series — about 89.7% against symptomatic COVID‑19 in the UK trial...